FMR1 Key Biomarker in Fragile X Syndrome- A Comprehensive Review


Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2024 | Volume : 01 | Issue : 02 | Page : –
    By

    Smitha Nayak,

  • Ramdas Bhat,

  1. UG scholar, Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore,, Karnataka, India
  2. Associate Professor, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka, India

Abstract

Fragile X Syndrome (FXS) is a complicated neurodevelopmental condition that causes intellectual disabilities, behavioural issues, and a variety of physical symptoms. Central to understanding FXS is the Fragile X Mental Retardation 1 (FMR1) gene, pivotal in the disorder’s pathogenesis. This review examines FMR1 as a key biomarker in FXS, drawing on recent research insights. The FMR1 gene, situated on the X chromosome, encodes the fragile X mental retardation protein (FMRP), which is essential for synaptic function and brain development. Mutations in FMR1, including CGG repeat expansions, cause FXS, resulting in cognitive and behavioural impairments. Advances in molecular genetics elucidate FMR1 dysfunction and its roles in FXS phenotypes. DNA testing for FMR1 mutations is used in diagnostic techniques, which is critical for accurate diagnosis and genetic counselling. FMR1 serves as a biomarker for disease monitoring and treatment evaluation. Emerging therapies targeting FMR1-related pathways offer promise for FXS intervention, highlighting FMR1 as a therapeutic target. Understanding FMR1’s roles in FXS pathophysiology informs precision medicine approaches. Elucidating FXS’s molecular basis and leveraging FMR1 as a biomarker aim to advance diagnostics, refine therapies, and improve outcomes. This review underscores FMR1’s pivotal role in FXS research and clinical practice, emphasizing its potential as a key biomarker for guiding precision medicine interventions.

Keywords: Fragile X Syndrome, FMR1 (Fragile X Mental Retardation 1) gene, Biomarker, Neurodevelopmental disorder, Precision medicine

[This article belongs to International Journal of Brain Sciences ]

How to cite this article:
Smitha Nayak, Ramdas Bhat. FMR1 Key Biomarker in Fragile X Syndrome- A Comprehensive Review. International Journal of Brain Sciences. 2024; 01(02):-.
How to cite this URL:
Smitha Nayak, Ramdas Bhat. FMR1 Key Biomarker in Fragile X Syndrome- A Comprehensive Review. International Journal of Brain Sciences. 2024; 01(02):-. Available from: https://journals.stmjournals.com/ijbs/article=2024/view=185691


References

  1. Liang Q, Liu Y, Liu Y, Duan R, Meng W, Zhan J, Xia J, Mao A, Liang D, Wu L. Comprehensive analysis of fragile X syndrome: full characterization of the FMR1 locus by long-read sequencing. Clin Chem. 2022 Dec 2;68(12):1529-40.
  2. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122(12):4314-22.
  3. Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathophysiology and clinical implications. Int J Mol Sci. 2020;21(12):4391.
  4. Kenny A, Wright D, Stanfield AC. EEG as a translational biomarker and outcome measure in fragile X syndrome. Translational Psychiatry. 2022 Jan 24;12(1):34.
  5. Dionne O, Corbin F. A new strategy to uncover fragile X proteomic biomarkers using the nascent proteome of peripheral blood mononuclear cells (PBMCs). Sci Rep. 2021 Jul 26;11(1):15148.
  6. Tabolacci E, Chiurazzi P. Epigenetics, fragile X syndrome and transcriptional therapy. Am J Med Genet A. 2013;161(11):2797-808.
  7. Zafarullah M, Tassone F. Molecular biomarkers in fragile X syndrome. Brain Sci. 2019 Apr 27;9(5):96.
  8. Bardoni B, Mandel JL, Fisch GS. FMR1 gene and fragile X syndrome. Am J Med Genet. 2023;97(2):153-63.
  9. Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: size matters. Clin Genet. 2011;80(3):214-25.
  10. Tassone F, Hagerman RJ, Chamberlain WD, Hagerman PJ. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet. 2000;97(3):195-203.
  11. Bailey Jr DB, Raspa M, Olmsted M, Holiday DB. Co‐occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am J Med Genet A. 2008;146(16):2060-9.
  12. Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, Visootsak J, Berry-Kravis E. Fragile X syndrome: a review of associated medical problems. Pediatrics. 2014;134(5):995-1005.
  13. Hersch JH, Saul RA. Health supervision for children with Fragile X syndrome. Pediatrics. 2011;127:994-1006.
  14. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry. 1996 May 1;35(5):599-605.
  15. Sobesky WE, Taylor AK, Pennington BF, Bennetto L, Porter D, Riddle J, Hagerman RJ. Molecular/clinical correlations in females with fragile X. Am J Med Genet. 1996;64(2):340-5.
  16. Schwartz CE, Dean J, Howard‐Peebles PN, Bugge M, Mikkelsen M, Tommerup N, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet. 1994;51(4):400-2.
  17. Wadell PM, Hagerman RJ, Hessl DR. Fragile X syndrome: psychiatric manifestations, assessment and emerging therapies. Curr Psychiatry Rev. 2013;9(1):53-8.
  18. Mila M, Alvarez‐Mora MI, Madrigal I, Rodriguez‐Revenga L. Fragile X syndrome: An overview and update of the FMR1 gene. Clin Genet. 2018;93(2):197-205.
  19. Tassone F, Hagerman PJ. Expression of the FMR1 gene. Cytogenet Genome Res. 2003;100(1-4):124-8.
  20. Oostra BA, Willemsen R. FMR1: a gene with three faces. Biochim Biophys Acta. 2019;1790(6):467-77.
  21. Eichler EE, Richards S, Gibbs RA, Nelson DL. Fine structure of the human FMR1 gene. Hum Mol Genet. 2023;2(8):1147-53.
  22. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, Hagerman PJ. Fragile X syndrome. Nature reviews Disease primers. 2017 Sep 29;3(1):1-9.
  23. Salcedo-Arellano MJ, Hagerman RJ, Martínez-Cerdeño V. Fragile X syndrome: clinical presentation, pathology and treatment. Gac Med Mex. 2020;156(1):60-6.
  24. Verkerk AJ, Pieretti M, Murthur A, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR1) containing CGG repeat expansions in fragile X syndrome. Nature. 1991;352(6332):606-10.
  25. Protic DD, Aishworiya R, Salcedo-Arellano MJ, Tang SJ, Milisavljevic J, Mitrovic F, et al. Fragile X syndrome: from molecular aspect to clinical treatment. Int J Mol Sci. 2022;23(4):1935.
  26. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med. 2019;7(8):584-7.
  27. Tassone F. Advanced technologies for the molecular diagnosis of fragile X syndrome. Expert Rev Mol Diagn. 2015;15(11):1465-73.
  28. Protic D, Salcedo-Arellano MJ, Dy JB, Potter LA, Hagerman RJ. New targeted treatments for fragile X syndrome. Curr Pediatr Rev. 2019;15(4):251-8.
  29. Castagnola S, Bardoni B, Maurin T. The search for an effective therapy to treat fragile X syndrome: dream or reality?. Front Synaptic Neurosci. 2017;9:15.
  30. Turner TJ, Zourray C, Schorge S, Lignani G. Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. J Neurochem. 2021;157(2):229-62.
  31. Lee AW, Ventola P, Budimirovic D, Berry-Kravis E, Visootsak J. Clinical development of targeted fragile X syndrome treatments: an industry perspective. Brain Sci. 2018;8(12):214.
  32. Tiwari P, Dwivedi R, Bansal M, Tripathi M, Dada R. Role of gut microbiota in neurological disorders and its therapeutic significance. J Clin Med. 2023;12(4):1650.
  33. Richter JD, Zhao X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat Rev Neurosci. 2021;22(4):209-22.
  34. Movaghar A, Page D, Scholze D, Hong J, DaWalt LS, Kuusisto F, et al. Artificial intelligence–assisted phenotype discovery of fragile X syndrome in a population-based sample. Genet Med. 2021;23(7):1273–80.
  35. Aderinto N, Olatunji G, Muili A, Kokori E, Edun M, Akinmoju O, et al. A narrative review of non-invasive brain stimulation techniques in neuropsychiatric disorders: current applications and future directions. Egypt J Neurol Psychiatry Neurosurg. 2024;60(1):50.
  36. Erickson C, Kaufmann W, Budimirovic D, Lachiewicz A, Haas-Givler B, Miller R, et al. Best Practices in Fragile X Syndrome Treatment Development. Brain Sci. 2018;8(12):224.
  37. Kumari D, Gazy I. Towards mechanism-based treatments for fragile X syndrome. Brain Sci. 2019;9(8):202.
  38. The European Commission grants Orphan Medicinal product designation for Zatolmilast, a potential first-in-class treatment being investigated for fragile X syndrome. Available at: https://www.shionogi.com/global/en/news/2024/04/20240411.html (Accessed: 02 June 2024).
  39. Crawford H, Abbeduto L, Hall SS, Hardiman R, Hessl D, Roberts JE, et al. Fragile X syndrome: an overview of cause, characteristics, assessment and management. Paediatr Child Health. 2020;30(11):400-3.
  40. Chadman KK, Adayev T, Udayan A, Ahmed R, Dai CL, Goodman JH, et al. Efficient Delivery of FMR1 across the Blood-Brain Barrier Using AAVphp Construct in Adult FMR1 KO Mice Suggests the Feasibility of Gene Therapy for Fragile X Syndrome. Genes. 2023;14(2):505.
  41. Nobile V, Pucci C, Chiurazzi P, Neri G, Tabolacci E. DNA methylation, mechanisms of FMR1 inactivation and therapeutic perspectives for fragile X syndrome. Biomolecules. 2021 Feb 16;11(2):296.
  42. Kulkarni P, Sevilimedu A. The known unknowns: missing pieces in in vivo models of fragile X syndrome. J Rare Dis Res Treat. 2020;5(1):1-9.
  43. Neul JL. Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research. J Clin Invest. 2024;134(5):e175036.
Regular Issue Subscription Review Article
Volume 01
Issue 02
Received 07/10/2024
Accepted 17/10/2024
Published 27/11/2024
Total Visits: 93


Loading citations…